BACKGROUND

HHV-8, also designated Kaposi’s sarcoma-associated herpesvirus, is associated with multicentric Castleman’s disease and primary effusion lymphoma, a rare type of non-Hodgkin lymphoma affecting the body cavities. HHV-8 K14 is expressed at the surfaces of infected cells solely during the lytic cycle. It interacts with human CD200R, a receptor expressed on myeloid cells that is involved in locally restricting macrophage activation. The interaction of HHV-8 K14 with CD200R allows the protein to locally restrain macrophage activation by inhibiting TNFα production. HHV-8 encodes a viral-cyclin that is homologous to cellular D-type cyclins, a class of positive cell cycle mediators that are physiologically regulated by the p27 cell cycle inhibitor. HHV-8 cyclin is not sensitive to p27, however, which may explain the coexistence of p27 and high proliferative index of HHV-8 observed in individuals with primary effusion lymphoma (PEL).

REFERENCES


SOURCE

HHV-8 (LN53) is a rat monoclonal antibody raised against recombinant HHV-8 corresponding to the latent nuclear antigen 1 molecule of HHV 8.

PRODUCT

Each vial contains 250 µl culture supernatant containing IgG2c, with < 0.1% sodium azide.

APPLICATIONS

HHV-8 (LN53) is recommended for detection of HHV-8 by immunofluorescence (starting dilution to be determined by researcher, dilution range 1:10-1:200) and immunohistochemistry (including paraffin-embedded sections) (starting dilution to be determined by researcher, dilution range 1:10-1:200).

SELECT PRODUCT CITATIONS


STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.